載入中
NASDAQHealthcareBiotechnology
最新資料
US$30.39
−US$1.23 · -3.89%
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
收盤時
US$30.39
−US$1.23 · -3.89%
盤後
US$30.80
+US$0.41 · +1.35%
10月12日 下午6:50 ET
盤中時間採用ET。市場資料可能有所延遲。
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$30.39
52週區間
目前US$30.39
盤中時間採用ET。市場資料可能有所延遲。
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$30.39
52週區間
目前US$30.39
| 項目（USD） | 2025會計年度 |
|---|---|
| 研究與開發 | 5963.2萬 USD |
| 銷售、一般及管理費用 | 1048.7萬 USD |
| 營業費用 | 7011.9萬 USD |
| 利息收入 | 197.4萬 USD |
| 折舊和攤銷 | 30.4萬 USD |
| 營業利益 | −7011.9萬 USD |
| 淨利 | −6391.3萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$51.40
上漲空間 69.13%評級樣本有限，僅3項
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2540.5萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1616萬0.02%787.4億 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1602.81萬0.16%98.74億 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF940.72萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO349.91萬0.03%139.17億 USD0.24%US$353.71-0.86%
Schwab U.S. Small-Cap ETFSCHA293.09萬0.01%218.24億 USD0.03%US$32.66-0.40%
Fidelity Fundamental Small-Mid Cap ETFFFSM166.47萬0.10%14.4億 USD0.43%US$34.02-0.32%
T. Rowe Price Small-Mid Cap ETFTMSL124.6萬0.04%30.87億 USD0.55%US$40.99-0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAFidelity Fundamental Small-Mid Cap ETFFFSMT. Rowe Price Small-Mid Cap ETFTMSLAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
